Gene Silencing Market, By Product & Service, By Application, By End Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

REPORT HIGHLIGHT

Gene Silencing Market size was valued at USD 9,940.32 Million in 2024, expanding at a CAGR of 13.64% from 2024 to 2032.

Gene silencing refers to the process of turning off or reducing the expression of specific genes. It can occur naturally through mechanisms like RNA interference (RNAi), where small RNA molecules prevent the translation of messenger RNA (mRNA) into proteins. Alternatively, gene silencing can be induced artificially using techniques like RNA-based therapies or CRISPR-based approaches to target and degrade specific mRNA or alter gene function. This process is essential for regulating gene expression, controlling cellular processes, and defending against viral infections, and it holds potential for therapeutic applications in treating genetic disorders and diseases.

Gene Silencing Market- Market Dynamics

Growing Demand for Personalized Medicine

The increasing demand for personalized medicine is a significant driver in the biotechnology market. Advances in genomics and molecular biology have enabled the development of treatments tailored to individual genetic profiles, improving efficacy and reducing side effects. As consumers and healthcare providers recognize the value of customized treatments, the adoption of personalized medicine is expanding across various therapeutic areas, including oncology, neurology, and rare diseases. This trend not only boosts demand for innovative biotechnological solutions but also accelerates investment in precision diagnostics, genetic testing, and targeted therapies, driving market growth.

Gene Silencing Market- Key Insights

According to our research analyst, the global Gene Silencing Market is expected to develop at a CAGR of approximately 13.64% between 2024-2032.
Segmented by Product & Service in 2023, the Products category dominated the market.
Based on Application, the Drug Discovery & Development segment generated the most income in 2023.
On the basis of region, in 2023, North America was the region with the highest revenue.

Gene Silencing Market- Segmentation Analysis:

The global Gene Silencing Market is divided into four categories: Product & Service, Application, End Use and Region.

The gene silencing market is segmented into products and services. Products include various tools like small interfering RNA (siRNA), short hairpin RNA (shRNA), and CRISPR/Cas9 systems, which are crucial for gene knockdown, gene editing, and molecular biology research. Services, on the other hand, include custom RNA synthesis, gene expression analysis, and silencing assays provided by research organizations and biotechnology companies. The product segment dominates the market due to the widespread use of RNA-based tools and CRISPR technologies in genetic research, drug discovery, and personalized medicine, which significantly contribute to market growth and innovation in gene-targeted therapies.

The gene silencing market is divided into drug discovery & development, therapeutics manufacturing, agricultural applications, and others. Among these, the drug discovery & development segment dominates the market. Gene silencing techniques are vital for identifying gene targets, understanding disease mechanisms, and validating new drug candidates. These applications are crucial in the development of targeted therapies, particularly in personalized medicine and oncology. As the demand for more precise and effective treatments grows, the use of gene silencing in drug discovery is expanding, driving significant market growth. The advancements in this area are essential for the development of novel therapeutic approaches for various diseases.

Gene Silencing Market- Geographical Insights

Geographically, the Gene Silencing Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America is a dominant region in the gene silencing market, driven primarily by the United States and Canada. The U.S. is a global leader in biotechnology research, with substantial investments in genetic research, drug discovery, and therapeutic development. The presence of major biotech companies, research institutions, and government funding agencies like the National Institutes of Health (NIH) significantly contributes to the market's growth. Additionally, the region's strong healthcare infrastructure and increasing adoption of personalized medicine and advanced gene-editing technologies further propel the demand for gene silencing products and services. Canada, with its growing biotech industry and collaborations in gene therapy, also contributes significantly to market expansion in the region, reinforcing North America's position as a leader in the gene silencing market.

Europe is another key player in the gene silencing market, with countries like Germany, the United Kingdom, and France leading the way. The region benefits from strong governmental support and funding for biotech research, along with an established pharmaceutical industry focused on genetic therapies. Europe's growing emphasis on personalized medicine, along with its advanced healthcare system, creates a favorable environment for gene silencing technologies. The presence of several top-tier research institutions, biotechnology firms, and clinical trials aimed at advancing gene therapy also fuels market growth. Additionally, the European Union's regulatory framework, which facilitates collaboration across member states, helps drive innovation and adoption of gene silencing products, making Europe one of the dominant regions in the global market.

Gene Silencing Market- Competitive Landscape:

The competitive dynamics of the gene silencing market are shaped by a mix of established players and emerging biotechnology companies focused on innovation. Key players like Revvity, Inc., Danaher, Agilent Technologies, GenScript, Merck KGaA, Thermo Fisher Scientific, Inc., Illumina, Bio-Rad Laboratories, Bio-Techne, and New England Biolabs, Inc. dominate the market with advanced gene silencing products and services. These companies invest heavily in R&D to enhance product performance and regulatory compliance. New entrants are introducing cutting-edge technologies, such as CRISPR-based tools, further enhancing the accuracy and efficiency of gene silencing. This intense competition drives continuous innovation, expanding the market and advancing genetic research and therapeutic development.

Recent Developments:

In February 2025, biotechnology company Junevity raised $10 million in seed funding to develop its RESET platform, utilizing AI and large-scale human data to identify transcription factors driving cellular damage. The platform targets these factors with siRNA therapeutics to restore cell health, initially focusing on Type 2 diabetes, obesity, and frailty. Preclinical data shows promising results, including improved glucose control and 30% fat-driven weight loss in mice without adverse effects. Junevity's approach allows for infrequent dosing (every 3–12 months), potentially improving patient compliance. The company aims to advance multiple clinical programs addressing age-related diseases.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENE SILENCING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Revvity, Inc.
Danaher
Agilent Technologies
GenScript
Merck KGaA
Thermo Fisher Scientific, Inc.
Illumina
Bio-Rad Laboratories
Bio-Techne
New England Biolabs, Inc.
Junevity
Others

GLOBAL GENE SILENCING MARKET, BY PRODUCT & SERVICE - MARKET ANALYSIS, 2019 - 2032

Products
RNAi

miRNA

siRNA

Others
CRISPR-Cas9

CRISPR Kits & Reagents

CRISPR Libraries

Others
Antisense Oligonucleotides
Others
Services

GLOBAL GENE SILENCING MARKET, BY APPLICATION - MARKET ANALYSIS, 2019 - 2032

Drug Discovery & Development
Neurology
Oncology
Infectious Diseases
Metabolic Diseases
Others
Therapeutics Manufacturing
Agricultural Applications
Others

GLOBAL GENE SILENCING MARKET, BY END USE - MARKET ANALYSIS, 2019 - 2032

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
CROs & CMOs
Others

GLOBAL GENE SILENCING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more